drugset / Trial / NCT07223983

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

NCT07223983 ↗

Phase 1 Active not recruiting 4 enrolled Yale University
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

Timeline

Start
2026-03-26
Primary completion
2027-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1 mg Other